Base de dados : LILACS
Pesquisa : D01.339.431.374.212 [Categoria DeCS]
Referências encontradas : 28 [refinar]
Mostrando: 1 .. 10   no formato [Longo]

página 1 de 3 ir para página          

  1 / 28 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Alecrim, Maria das Graças Costa
Texto completo
Id: biblio-1002690
Autor: Pinto, Raquel de Medeiros; Sampaio, Vanderson de Souza; de Melo, Gisely Cardoso; Alecrim, Maria das Graças Costa; Mattos, Karine; Perdomo, Renata Trentin; Cordeiro, Sabrine da Costa; Parente, Ana Flávia Alves; de Carvalho, Lídia Raquel; Mendes, Rinaldo Pôncio; Lacerda, Marcus Vinícius Guimarães; Monteiro, Wuelton Marcelo; Weber, Simone Schneider.
Título: Overview of artemisinin effectiveness during outset years of its implementation in the western Brazilian Amazon
Fonte: Mem. Inst. Oswaldo Cruz;114:e190075, 2019. tab, graf.
Idioma: en.
Projeto: CAPES; . RMP; . KM; . CAPES.
Resumo: BACKGROUND The elimination of malaria depends on the blocking of transmission and of an effective treatment. In Brazil, artemisinin therapy was introduced in 1991, and here we present a performance overview during implementation outset years. METHODS It is a retrospective cohort (1991 to 2002) of patients treated in a tertiary centre of Manaus, with positive microscopic diagnosis of Plasmodium falciparum malaria, under treatment with using injectable or rectal artemisinin derivatives, and followed over 35-days to evaluate parasite clearance, death and recurrence. FINDINGS This cohort outcome resulted 97.6% (1554/1593) of patients who completed the 35-day follow-up, 0.6% (10/1593) of death and 1.8% (29/1593) of follow-up loss. All patients that died and those that presented parasitaemia recurrence had pure P. falciparum infections and received monotherapy. Considering patients who completed 35-day treatment, 98.2% (1527/1554) presented asexual parasitaemia clearance until D4 and 1.8% (27/1554) between D5-D10. It is important to highlight that had no correlation between the five treatment schemes and the sexual parasite clearance. Finally, it is noteworthy that we were able to observe also gametocytes carriage during all follow-up (D0-D35). MAIN CONCLUSIONS Artemisinin derivatives remained effective in the treatment of falciparum malaria during first 12-years of use in north area of Brazil.
Responsável: BR1.1 - BIREME


  2 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-911265
Autor: Okunlola, A. I; Okunlola, C. K; Okani, C. O; Adewole, O. S; Ofusori, D. A; Komolafe, O. A; Ojo, S. K; Bejide, R. A; Ayoka, A. O; Ojewole, J. A. O.
Título: Histological studies on the retina and cerebellum of Wistar rats treated with ArteetherTM
Fonte: Braz. j. morphol. sci = Rev. bras. ciênc. morfol;31(1):28-32, 1/3/2014. ilus.
Idioma: en.
Resumo: Introduction: Arteether TM, a derivative of artemisinin, is among the recent drugs that have given renewed hope for combating malarial menace. The present study investigated the effects of arteetherTM on the histology of the retina and cerebellum of Wistar rats. Materials and Methods: Twenty adult albino Wistar rats weighing 150-200 g, were randomly divided into four groups (A, B, C and D) of five animals each and used for this study. Group A rats were given intramuscular (i.m.) arteetherTM (3 mg/kg b.w.) daily for 3 days. Group B rats were given i.m. arteetherTM (6 mg/kg b.w.) daily for 3 days. Group C rats were also given i. m. of arteetherTM (3 mg/kg b. w.) daily for 3 days, and the same dose was repeated at two-weekly intervals for 4 further weeks; while Group D rats which received normal saline (0.9 % w/v, 3 ml/kg b.w.), served as controls. At the end of the experiment, the rats were sacrificed by cervical dislocation. The retina and cerebellum were excised and processed routinely for histopathology changes, using haematoxylin and eosin stain (H & E), as well as Nissl stain. Results: Results obtained showed normal cellular components of the retina and cerebellum in all groups, and no cyto-pathological changes were observed. Conclusion: Thus, this study showed that under light microscopic examination, therapeutic doses of arteetherTM caused no significant cyto-pathologic changes in the retina and cerebellum of Wistar rats.(AU)
Responsável: BR1.1 - BIREME


  3 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-906979
Autor: Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Título: Desinvestimento do medicamento artemeter para o tratamento de Malária Grave / Disinvestment of the drug artemether for the treatment of Serious Malaria.
Fonte: Brasília; CONITEC; out. 2017. tab.
Idioma: pt.
Resumo: CONTEXTO: A malária é uma doença parasitária infecciosa aguda causada por protozoários do gênero Plasmodium e representa um grave problema de saúde pública. No Brasil, há três espécies associadas à malária em seres humanos: P. falciparum, P. vivax e P. malariae. O demandante solicitou o desinvestimento do medicamento artemeter 80 mg/ml, mantendo apenas o artesunato 60 mg/ml como opção de tratamento injetável com derivado de artemisinina para malária grave. A recomendação de retirada do artemeter fundamenta-se em orientação do guia de tratamento da Organização Mundial de Saúde (OMS), publicado em 2015, que orienta que o tratamento de adultos e crianças com malária grave (incluindo as gestantes em todos os trimestres e mulheres lactantes) deve ser feito, preferencialmente, com artesunato intravenoso ou intramuscular. TECNOLOGIA SOLICITADA PARA DESINVESTIMENTO: Artemeter 80 mg/ml.: Tratamento da malária grave. EVIDÊNCIAS CIENTÍFICAS: Com o objetivo de avaliar se artesunato injetável é uma melhor opção terapêutica que o artemeter injetável para o tratamento da malária grave, em termos de eficácia, efetividade e segurança, foram pesquisadas evidências científicas comparando os dois medicamentos. Foi selecionada uma revisão sistemática da Cochrane que mostrou que o risco de mortalidade por todas as causas foi significativamente menor com o artesunato do que com o artemeter. O artesunato reduziu o risco de hipoglicemia, como evento adverso aos tratamentos, em relação ao artemeter. Não houve diferenças significativas entre os tratamentos na resolução do coma, no tempo para clearance do parasita e no tempo para desaparecimento da febre. IMPACTO ORÇAMENTÁRIO: Embora o custo de tratamento com artesunato 60 mg/mL seja maior do que com o artemeter 80 mg/ml, o demandante informou que não vai aumentar a quantidade de artesunato comprada, visto que os casos de malária grave estão diminuindo. RECOMENDAÇÃO DA CONITEC: Pelo exposto, os membros do Plenário da CONITEC, presentes na 56ª reunião ordinária, deliberaram que o tema fosse submetido à consulta pública com recomendação preliminar favorável ao desinvestimento do artemeter para tratamento da malária grave. CONSULTA PÚBLICA: Foi recebida somente 1 contribuição sobre experiência de profissional de saúde que concordou totalmente com a recomendação da CONITEC. : Os membros da CONITEC deliberaram por recomendar a exclusão do medicamento artemeter para o tratamento de malária grave. DECISÃO: A Portaria nº 42, de 9 de outubro de 2017, tornou pública a decisão de excluir o medicamento artemeter para o tratamento de Malária Grave, no âmbito do Sistema Único de Saúde ­ SUS.(AU)
Responsável: BR1.1 - BIREME


  4 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-839493
Autor: Ye, Xuan-Yi; Ling, Qing-Zhi; Chen, Shao-Jun.
Título: Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
Fonte: Braz. j. pharm. sci;53(2):e16087, 2017. tab, graf.
Idioma: en.
Projeto: Zhejiang Provincial Natural Science Foundation of China; . Ningbo Municipal Natural Science Foundation; . Administration of Traditional Chinese Medicine of Zhejiang Province.
Resumo: ABSTRACT The discovery of arteannuin (qinghaosu) in the 20th Century was a major advance for medicine. Besides functioning as a malaria therapy, arteannuin is a pharmacological agent in a range of other diseases, but its mechanism of action remains obscure. In this study, the reverse docking server PharmMapper was used to identify potential targets of arteannuin. The results were checked using the chemical-protein interactome servers DRAR-CPI and DDI-CPI, and verified by AutoDock Vina. The results showed that neprilysin (also known as CD10), a common acute lymphoblastic leukaemia antigen, was the top disease-related target of arteannuin. The chemical-protein interactome and docking results agreed with those of PharmMapper, further implicating neprilysin as a potential target. Although experimental verification is required, this study provides guidance for future pharmacological investigations into novel clinical applications for arteannuin.
Responsável: BR1.1 - BIREME


  5 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-787558
Autor: Lobo, Lis; Sousa, Bruno de; Cabral, Lília; Cristiano, Maria LS; Nogueira, Fátima.
Título: Highly active ozonides selected against drug resistant malaria
Fonte: Mem. Inst. Oswaldo Cruz;111(7):450-453tab.
Idioma: en.
Projeto: CAPES; . FCT; . FCT.
Resumo: Ever increasing multi-drug resistance by Plasmodium falciparum is creating new challenges in malaria chemotherapy. In the absence of licensed vaccines, treatment and prevention of malaria is heavily dependent on drugs. Potency, range of activity, safety, low cost and ease of administration are crucial issues in the design and formulation of antimalarials. We have tested three synthetic ozonides NAC89, LC50 and LCD67 in vitro and in vivo against multidrug resistant Plasmodium. In vitro, LC50 was at least 10 times more efficient inhibiting P. falciparum multidrug resistant Dd2 strain than chloroquine and mefloquine and as efficient as artemisinin (ART), artesunate and dihydroartemisinin. All three ozonides showed high efficacy in clearing parasitaemia in mice, caused by multi-drug resistant Plasmodium chabaudi strains, by subcutaneous administration, demonstrating high efficacy in vivo against ART and artesunate resistant parasites.
Responsável: BR1.1 - BIREME


  6 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-774952
Autor: Zuluaga-Idarraga, Lina Marcela; Tamayo Perez, María-Eulalia; Aguirre-Acevedo, Daniel Camilo.
Título: Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis / Eficacia terapéutica de esquemas de Primaquina usados como alternativa al tratamiento estándar en la prevención de recaídas por Plasmodium vivax: Una revisión sistemática y meta-análisis
Fonte: Colomb. med;46(4):183-191, Oct.-Dec. 2015. tab.
Idioma: en.
Resumo: Objective: To compare efficacy and safety of primaquine regimens currently used to prevent relapses by P. vivax. Methods: A systematic review was carried out to identify clinical trials evaluating efficacy and safety to prevent malaria recurrences by P. vivax of primaquine regimen 0.5 mg/kg/day for 7 or 14 days compared to standard regimen of 0.25 mg/kg/day for 14 days. Efficacy of primaquine according to cumulative incidence of recurrences after 28 days was determined. The overall relative risk with fixed-effects meta-analysis was estimated. Results: For the regimen 0.5 mg/kg/day/7 days were identified 7 studies, which showed an incidence of recurrence between 0% and 20% with follow-up 60-210 days; only 4 studies comparing with the standard regimen 0.25 mg/kg/day/14 days and no difference in recurrences between both regimens (RR= 0.977, 95% CI= 0.670 to 1.423) were found. 3 clinical trials using regimen 0.5 mg/kg/day/14 days with an incidence of recurrences between 1.8% and 18.0% during 330-365 days were identified; only one study comparing with the standard regimen (RR= 0.846, 95% CI= 0.484 to 1.477). High risk of bias and differences in handling of included studies were found. Conclusion: Available evidence is insufficient to determine whether currently PQ regimens used as alternative rather than standard treatment have better efficacy and safety in preventing relapse of P. vivax. Clinical trials are required to guide changes in treatment regimen of malaria vivax.

Objetivo: Comparar la eficacia y seguridad de los esquemas de primaquina actualmente usados para prevenir las recaídas de malaria por P. vivax. Métodos: A través de una revisión sistemática se identificaron ensayos clínicos que evaluaran la eficacia y seguridad para prevenir recurrencias por P. vivax del régimen de primaquina 0.5 mg/Kg/día por 7 o 14 días comparado al régimen estándar de 0.25 mg/Kg/día por 14 días. Se determinó la eficacia de primaquina con la incidencia acumulada de recurrencias posterior a 28 días. Se estimó el riesgo relativo global con un meta-análisis de efectos fijos. Resultados: Se identificaron 7 ensayos clínicos para el régimen 0.5 mg/Kg/día/7 días que mostraron una incidencia de recurrencias entre 0% y 20% con un seguimiento de 60 a 210 días; solo 4 estudios compararon con el régimen estándar y no se encontraron diferencias en las recurrencias entre ambos esquemas (RR= 0.977; IC 95%= 0.670-1.423). Se identificaron tres ensayos clínicos que usaron el esquema 0.5 mg/Kg/día/14 días con una incidencia de recurrencias entre 1.8% y 18.0% para 330 a 365 días; solo un estudio comparó con el régimen estándar (RR= 0.846; IC 95%= 0.484-1.477). Se encontró alto riesgo de sesgo y diferencias en la conducción de los estudios incluidos. Conclusión: No hay suficiente evidencia para determinar si los regímenes de primaquina usados como alternativas al tratamiento estándar tienen mejor eficacia para prevenir las recaídas de P. vivax. Se requieren ensayos clínicos para orientar los cambios en el esquema de tratamiento de este tipo de malaria.
Responsável: CO332 - Facultad de Medicina


  7 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-745456
Autor: Villalva Rojas, Ofelia del Rosario.
Título: Comparación de las biodisponibilidades in vitro de Artesunato tabletas de diferentes procedências / Comparación de las bioavailability in vitro Artesunate tablets from different sources.
Fonte: Rio de Janeiro; s.n; 2014. 80 p. ilus, mapas, tab, graf.
Idioma: pt.
Tese: Apresentada a Escola Nacional de Saúde Pública Sergio Arouca para obtenção do grau de Mestre.
Resumo: En las décadas pasadas se incrementó los casos de malaria en los países de la cuenca amazónica, inclu-yendo la aparición de P. falciparum y la resistencia a los medicamentos de primera línea; Cloroquina y Sulfadoxina / Pirimetamina, adicionalmente en estudios recientes se reportaron deficiencias en la calidad de los medicamentos antimalaricos43. Por lo que Perú cambió su esquema de tratamiento para P. falcipa-rum no complicada: con Mefloquina más Artesunato en la selva y Sulfadoxina / Pirimetamina en la costa norte. En el esquema de tratamiento de Perú, se utiliza un medicamento genérico nacional (multifuente) que no ha demostrado ser intercambiable con el medicamento original, debido a que la regulación actual no ha implementado este requisito; aunque en la Ley 29459, ya se señale como parte de los requisitos del Registro Sanitario y que se espere entre en vigencia gradualmente. Objetivo: comparar las disponibilida-des in vitro de las tabletas de Artesunato usadas por la estrategia sanitaria de malaria en Perú, con las tabletas de Artesunato fabricadas en empresas precalificadas por la Organización Mundial de la Salud (OMS) en Brasil y Ghana. Metodología: para los ensayos de control de calidad y pruebas de cinética de disolución se utilizó la Farmacopea Non Standard de Los Estados Unidos, las guías de FDA y OMS...

Malaria cases have increased in the countries of the Amazon basin in the past decades, including the ap-pearance of P. falciparum and resistance to first-line drugs; Chloroquine and Sulfadoxine / Pyrimethamine. In recent studies were reported deficiencies in the quality of antimalarial drugs, because of that Peru changed the treatment scheme for uncomplicated P. falciparum, and begin to use Mefloquine plus Arte-sunate for Amazon Area and Sulfadoxine / Pyrimethamine on the North coast. In Peruvian treatment scheme, is used a national generic drug (multisource), which one did not demonstrate to be interchangea-ble with the innovator, because, this is not yet a requirement to get the Sanitary Register, according to Law 29459, and hopefully it will be implemented gradually. Objective: compare the in vitro availability of Artesunate tablets used by the health strategy against malaria in Peru, with Artesunate tablets manufac-tured by WHO prequalified manufactures from Brazil and Ghana. Methodology: testing and dissolution kinetics tests were performed with Non Standard Pharmacopoeia of the United States, FDA and WHO guidelines...
Responsável: BR526.1 - Biblioteca de Saúde Pública


  8 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-743477
Autor: Frezza, Tarsila Ferraz; Oliveira, Claudineide Nascimento Fernandes de; Rehder, Vera Lúcia Garcia; Boaventura Junior, Sinésio; Allegretti, Silmara Marques; Banin, Tamy Midori.
Título: Tegumentary changes in two diferent strains of schistosoma mansoni treated with artemisinin and artesunic acid
Fonte: Rev. patol. trop;42(3):309-321, 2013. ilus.
Idioma: en.
Resumo: Different strains of Schistosoma mansoni can respond differently to conventional and experimental treatments. Therefore, the responses to potential schistosomicidal drugs must be checked with different parasite strains. This work aimed to analyze changes caused by different concentrations of artemisinin or artesunic acid administered on different days in the teguments of adult S. mansoni belonging to two Brazilian strains (BH and SJ), using scanning electron microscopy (SEM). Infected mice were treated with 300 or 500 mg/kg of artemisinin and artesunic acid, 30 or 45 days post infection. Fifteen days after treatment, worms were examined by SEM. Altered teguments were observed in males and females on both days of treatment with both compounds, but the injury with artesunic acid was more intense. The treatment utilizing 500 mg/kg of artesunic acid against the BH strain 30 days after the infection proved to be particularly effective, resulting in erosion, peeling, sensory structure damage, and vesicle formation on the tegument of males and females. It is concluded that artemisinin and artesunic acid showed qualitatively similar tegumentary changes in both genders of the BH and SJ parasite strains. However, changes induced by artesunic acid were more severe for the BH strain, which demonstrates greater susceptibility of this strain to this experimental treatment...

Alterações tegumentares em duas diferentes linhagens de Schistosoma mansoni submetidas a tratamento com artemisinina e ácido artesúnicoDiferentes linhagens de Schistosoma mansoni podem responder de formas distintas a tratamentos experimentais. Portanto, ensaios com potenciais fármacos esquistossomicidas necessitam ser realizados com várias linhagens. Este trabalho visou analisar as alterações causadas por diferentes concentrações de artemisinina e ácido artesúnico, administradas em diferentes dias, sobre o tegumento de adultos de S. mansoni de duas linhagens brasileiras (BH e SJ), utilizando-se microscopia eletrônica de varredura (MEV). Os camundongos infectados foram tratados com 300 e 500 mg/kg de artemisinina ou ácido artesúnico, 30 ou 45 dias após a infecção. Após 15 dias do tratamento, os vermes foram analisados pela MEV. A destruição do tegumento foi observada em machos e fêmeas nos dois dias de tratamento com ambos os compostos, mas observou-se que o ácido artesúnico provocou uma destruição mais intensa. O tratamento realizado com 500 mg/g de ácido artesúnico contra parasitos da linhagem BH, 30 dias após a infecção, mostrou ser o mais efetivo, resultando em erosão, descamação, destruição das estruturas sensoriais e formação de vesículas nos machos e nas fêmeas. Ficou evidenciado que as linhagens BH e SJ apresentaram alterações tegumentares diferentes quanto à intensidade, com ambos os compostos. No entanto, a destruição do tegumento foi mais intensa na linhagem BH, especialmente com o ácido artesúnico, o que demonstrou maior suscetibilidade desta linhagem a esse tratamento experimental...
Responsável: BR15.1 - Biblioteca de Ciências Biomédicas


  9 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-719465
Autor: Bolina, C.O.; Marchese, J.A.; Paladini, M.V.; Pinnow, C.; Benin, G.; Sousa, I.M.O.; Foglio, M.A..
Título: Dissimilaridade genética em variedades de Artemisia annua L. embasada em caracteres agronômicos, fisiológicos e fitoquímicos / Genetic dissimilarity in varieties of Artemisia annua L. based on agronomic, physiological and phytochemical characters
Fonte: Rev. bras. plantas med;16(2,supl.1):356-363, 2014. ilus, tab.
Idioma: pt.
Resumo: O presente estudo objetivou estimar a variabilidade genética existente entre caracteres agronômicos, fisiológicos e fitoquímicos em variedades de A. annua. O delineamento experimental foi inteiramente casualizado e os tratamentos foram as variedades Artemis, 2/39x5x3M, e 2/39x1V de A. annua, submetidas a avaliações agronômicas, fisiológicas e fitoquímicas. Para a realização das estimativas de distância genética foram geradas matrizes de dissimilaridade utilizando a distância Euclidiana e os métodos de agrupamento de Tocher e UPGMA. Além disso, avaliou-se a importância relativa dos caracteres para divergência genética pelo método de Singh. As análises foram realizadas pelo software Genes e os dendrogramas obtidos pelo NTSYS. A presença de variabilidade genética dentro das variedades permitiu a identificação de acessos dissimilares e com média elevada para as características estudadas. O número de ramificações, concentração intracelular de CO2, e o rendimento de óleo essencial foram os caracteres que mais contribuíram para a dissimilaridade genética de A. annua. Os acessos B24, C5 e C32 foram os mais promissores dentro das variedades e devem ser conservados para futuras hibridações, sendo que as hibridações mais promissoras na obtenção de populações segregantes desejadas são B24 x C5, B24 x C32 e C5 x C32.

This study aimed to estimate the genetic variability among agronomic, physiological, and phytochemical characters in varieties of A. annua. The experimental design was completely randomized and the treatments were the varieties Artemis, 2/39x5x3M and 2/39x1V of A. annua, subject to agronomic, physiological and phytochemical evaluations. To estimate the genetic distances, dissimilarity matrices were generated using the Euclidean distance and the Tocher and UPGMA grouping methods. Moreover, we evaluated the relative importance of the characters for genetic divergence through the method of Singh. The analyses were performed in the Genes software and the dendrograms were obtained from the NTSYS program. The presence of genetic variability within the varieties allowed the identification of dissimilar accessions with high average for all traits. The number of branches, intracellular concentration of CO2 and oil yield were the traits that contributed most to the genetic dissimilarity of A. annua. The accessions B24, C5 and C32 were the most promising within the populations and must be conserved for future crossings, and the most promising crosses to obtain the desired segregant populations were B24 x C5, B24 x C32 and C5 x C32.
Responsável: BR1.1 - BIREME


  10 / 28 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-697149
Autor: Vreden, Stephen GS; Jitan, Jeetendra K; Bansie, Rakesh D; Adhin, Malti R.
Título: Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether
Fonte: Mem. Inst. Oswaldo Cruz;108(8):968-973, 6/dez. 2013. tab, graf.
Idioma: en.
Resumo: The emerging resistance to artemisinin derivatives that has been reported in South-East Asia led us to assess the efficacy of artemether-lumefantrine as the first line therapy for uncomplicated Plasmodium falciparum infections in Suriname. This drug assessment was performed according to the recommendations of the World Health Organization in 2011. The decreasing number of malaria cases in Suriname, which are currently limited to migrating populations and gold miners, precludes any conclusions on artemether efficacy because adequate numbers of patients with 28-day follow-up data are difficult to obtain. Therefore, a comparison of day 3 parasitaemia in a 2011 study and in a 2005/2006 study was used to detect the emergence of resistance to artemether. The prevalence of day 3 parasitaemia was assessed in a study in 2011 and was compared to that in a study in 2005/2006. The same protocol was used in both studies and artemether-lumefantrine was the study drug. Of 48 evaluable patients in 2011, 15 (31%) still had parasitaemia on day 3 compared to one (2%) out of 45 evaluable patients in 2005/2006. Overall, 11 evaluable patients in the 2011 study who were followed up until day 28 had negative slides and similar findings were obtained in all 38 evaluable patients in the 2005/2006 study. The significantly increased incidence of parasite persistence on day 3 may be an indication of emerging resistance to artemether.
Responsável: BR1.1 - BIREME



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde